Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Peregrine Capital Management LLC

Peregrine Capital Management LLC lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 3.5% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 99,346 shares of the medical equipment provider's stock after selling 3,580 shares during the period. Peregrine Capital Management LLC owned approximately 0.14% of Lantheus worth $8,887,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. CWM LLC grew its position in shares of Lantheus by 63.0% in the 3rd quarter. CWM LLC now owns 750 shares of the medical equipment provider's stock worth $82,000 after buying an additional 290 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of Lantheus by 57.1% in the 3rd quarter. Exchange Traded Concepts LLC now owns 1,266 shares of the medical equipment provider's stock worth $139,000 after buying an additional 460 shares during the last quarter. Creative Planning grew its position in shares of Lantheus by 5.4% in the 3rd quarter. Creative Planning now owns 24,988 shares of the medical equipment provider's stock worth $2,742,000 after buying an additional 1,274 shares during the last quarter. Bleakley Financial Group LLC purchased a new position in shares of Lantheus in the 3rd quarter worth approximately $231,000. Finally, Net Worth Advisory Group purchased a new position in shares of Lantheus in the 3rd quarter worth approximately $218,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Trading Down 3.2 %

NASDAQ LNTH traded down $2.61 on Friday, hitting $78.23. 899,189 shares of the company's stock traded hands, compared to its average volume of 803,847. Lantheus Holdings, Inc. has a 1-year low of $56.44 and a 1-year high of $126.89. The firm's 50-day moving average price is $90.31 and its two-hundred day moving average price is $97.06. The firm has a market capitalization of $5.44 billion, a PE ratio of 13.02 and a beta of 0.44.

Remove Ads

Insider Buying and Selling at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the sale, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of analyst reports. The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price objective on the stock. JMP Securities reiterated a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Truist Financial reiterated a "buy" rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, StockNews.com cut shares of Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and a consensus price target of $131.86.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.